Literature DB >> 11581233

Departmental consumption of antibiotic drugs and subsequent resistance: a quantitative link.

L Leibovici1, R Berger, T Gruenewald, J Yahav, Y Yehezkelli, G Milo, M Paul, Z Samra, S D Pitlik.   

Abstract

OBJECTIVE: To look for a quantitative model linking departmental consumption of antibiotic drugs to the subsequent isolation of resistant hospital-acquired coliform pathogens.
MATERIALS AND METHODS: Included in the study were all patients with hospital-acquired bloodstream infections caused by a coliform pathogen, detected in six departments of internal medicine of one university hospital during the period 1991-1996, who had not been hospitalized in the month before the infection (n = 394). Departmental consumption of antibiotics in the year before the infection [expressed as defined daily dosages (DDD)/100 patient days], antibiotic treatment given to the individual patient before the infection, the day of hospital stay on which the infection occurred, and the department and the calendar year were all included in a logistic model to predict the isolation of a resistant pathogen. We looked at five drugs: gentamicin, amikacin, cefuroxime, ceftazidime and ciprofloxacin.
RESULTS: Five logistic models were fitted for the resistance to each of the antibiotic drugs. The multivariable-adjusted odds ratios for a pathogen resistant to the specific antibiotic were 1.03 [95% confidence interval (CI) 0.70-1.50] for gentamicin, 1.80 (95% CI 1.00-3.24) for amikacin, 1.12 (95% CI 1.02-1.23) for cefuroxime, 1.45 (95% CI 1.19-1.76) for ceftazidime and 1.06 (95% CI 0.57-1.97) for ciprofloxacin, per 1 DDD/100 patient days.
CONCLUSIONS: The departmental consumption of cephalosporin drugs and amikacin in six autonomous departments of medicine in the same hospital was associated with a measurable and statistically significant increase in the probability of infection caused by a resistant pathogen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581233     DOI: 10.1093/jac/48.4.535

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.

Authors:  P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal:  J Hosp Infect       Date:  2010-12       Impact factor: 3.926

2.  Development and evaluation of an ontology for guiding appropriate antibiotic prescribing.

Authors:  Tiffani J Bright; E Yoko Furuya; Gilad J Kuperman; James J Cimino; Suzanne Bakken
Journal:  J Biomed Inform       Date:  2011-10-11       Impact factor: 6.317

3.  Quantifying the associations between antibiotic exposure and resistance - a step towards personalised antibiograms.

Authors:  L Sanden; M Paul; L Leibovici; S Andreassen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-26       Impact factor: 3.267

4.  The effect of empiric antibiotic therapy on mortality in debilitated patients with dementia.

Authors:  S Reisfeld; M Paul; B S Gottesman; P Shitrit; L Leibovici; M Chowers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-26       Impact factor: 3.267

5.  Antimicrobial use and antimicrobial resistance: a population perspective.

Authors:  Marc Lipsitch; Matthew H Samore
Journal:  Emerg Infect Dis       Date:  2002-04       Impact factor: 6.883

6.  Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.

Authors:  C García-Rey; L Aguilar; F Baquero; J Casal; J E Martín
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

7.  Presence of bacteriuria caused by trimethoprim resistant bacteria in patients prescribed antibiotics: multilevel model with practice and individual patient data.

Authors:  P T Donnan; L Wei; D T Steinke; G Phillips; R Clarke; A Noone; F M Sullivan; T M MacDonald; P G Davey
Journal:  BMJ       Date:  2004-05-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.